Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are multipotent stromal cells harvested from umbilical cord tissue, such as Wharton's jelly. These cells are characterized by their high proliferative capacity, low immunogenicity, and potent immunomodulatory and regenerative properties. In the treatment of chronic temporomandibular joint (TMJ) disease, UC-MSCs are administered via intra-articular injection to promote the repair of damaged articular cartilage and bone while modulating the local inflammatory environment. Erciyes University is currently evaluating the safety and efficacy of these cells in a Phase I/II clinical trial (NCT04730323), comparing their therapeutic potential against adipose tissue-derived stromal vascular fraction (SVF) in patients with chronic TMJ disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cells (Erciyes University).